Cancer Research and Treatment

Original Articles

Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: Hye In Lee, Bum-Sup Jang, Ji Hyun Chang, Eunji Kim, Tae Hoon Lee, Jeong Hwan Park, Eui Kyu Chie; Received June 2, 2024 Accepted December 13, 2024 Published online December 16, 2024; DOI: https://doi.org/10.4143/crt.2024.521 [Accepted]

Abstract PDF: Purpose
This study aimed to investigate the dynamic changes in the microbiome of patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy (nCRT), focusing on the relationship between the microbiome and response to nCRT.
Materials and Methods
We conducted a longitudinal study involving 103 samples from 26 patients with LARC. Samples were collected from both the tumor and normal rectal tissues before and after nCRT. Diversity, taxonomic, and network analyses were performed to compare the microbiome profiles across different tissue types, pre- and post-nCRT time-points, and nCRT responses.
Results
Between the tumor and normal tissue samples, no differences in microbial diversity and composition were observed. However, when pre- and post-nCRT samples were compared, there was a significant decrease in diversity, along with notable changes in composition. Non-responders exhibited more extensive changes in their microbiome composition during nCRT, characterized by an increase in pathogenic microbes. Meanwhile, responders had relatively stable microbiome communities with more enriched butyrate-producing bacteria. Network analysis revealed distinct patterns of microbial interactions between responders and non-responders, where butyrate-producing bacteria formed strong networks in responders, while opportunistic pathogens formed strong networks in non-responders. A Bayesian network model for predicting the nCRT response was established, with butyrate-producing bacteria playing a major predictive role.
Conclusion
Our study demonstrated a significant association between the microbiome and nCRT response in LARC patients, leading to the development of a microbiome-based response prediction model. These findings suggest potential applications of microbiome signatures for predicting and optimizing nCRT treatment in LARC patients.

237 View
17 Download

Higher Microbial Abundance and Diversity in Bronchus-Associated Lymphoid Tissue (BALT) Lymphomas than in Non-Cancerous Lung Tissues: Jung Heon Kim, Jae Sik Kim, Noorie Choi, Jiwon Koh, Yoon Kyung Jeon, Ji Hyun Chang, Eung Soo Hwang, Il Han Kim; Received July 24, 2024 Accepted September 29, 2024 Published online September 30, 2024; DOI: https://doi.org/10.4143/crt.2024.689 [Accepted]

Abstract PDF: Purpose
It is well known that the majority of the extranodal marginal zone lymphomas of mucosa-associated lymphoid tissues (MALT lymphomas) are associated with microbiota, e.g., gastric MALT lymphoma with Helicobacter pylori. In general, they are very sensitive to low-dose radiotherapy and chemotherapeutic agents. The microbiota profile is not clearly elucidated in bronchus-associated lymphoid tissue (BALT) lymphoma, a rare type of MALT lymphoma in the lung. Thus, this study aimed to clarify the intratumor microbiome in BALT lymphoma using the third-generation NGS method.
Materials and Methods
DNAs were extracted from 12 formalin-fixed paraffin-embedded (FFPE) tumor tissues obtained from BALT lymphoma patients diagnosed between 1990 and 2016. 16S rRNA gene was amplified by polymerase chain reaction. Amplicons were sequenced using a Nanopore platform. Next-generation sequencing analysis was performed to assess microbial profiles. For comparison, FFPE specimens from nine non-cancerous lung tissues were also analyzed.
Results
Specific bacterial families including Burkholderiaceae, Bacillaceae, and Microbacteriaceae were associated with BALT lymphoma by a linear discriminant analysis effect size approach. Although the number of specimens was limited, BALT lymphomas exhibited significantly higher microbial abundance and diversity with distinct microbial composition patterns and correlation networks than non-cancerous lung tissues.
Conclusion
This study provides the first insight into intratumor microbiome in BALT lymphoma using the third-generation NGS method. A distinct microbial composition suggests the presence of a unique tumor microenvironment of BALT lymphoma.

519 View
53 Download

Breast cancer

Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy: Dowook Kim, Jin Ho Kim, In Ah Kim, Ji Hyun Chang, Kyung Hwan Shin; Cancer Res Treat. 2023;55(2):592-602. Published online October 11, 2022; DOI: https://doi.org/10.4143/crt.2022.998

Abstract PDF Supplementary Material PubReader ePub

Purpose
The utility of postmastectomy radiation therapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) is highly controversial. This study evaluated the impact of PMRT according to pathologic nodal status after modern NAC.
Materials and Methods
We retrospectively reviewed 682 patients with clinical stage II-III breast cancer who underwent NAC and mastectomy from 2013 to 2017. In total, 596 patients (87.4%) received PMRT, and 86 (12.6%) did not. We investigated the relationships among locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and various prognostic factors. Subgroup analyses were also performed to identify patients who may benefit from PMRT.
Results
The median follow-up duration was 67 months. In ypN+ patients (n=368, 51.2%), PMRT showed significant benefits in terms of LRRFS, DFS, and OS (all p < 0.001). In multivariate analyses, histologic grade (HG) III (p=0.002), lymphovascular invasion (LVI) (p=0.045), and ypN2-3 (p=0.02) were significant risk factors for poor LRRFS. In ypN1 patients with more than two prognostic factors among luminal/human epidermal growth factor receptor-2–negative subtype, HG I-II, and absence of LVI, PMRT had no significant effect on LRRFS (p=0.18). In ypN0 patients (n=351, 48.8%), PMRT was not significantly associated with LRRFS, DFS, or OS. However, PMRT showed better LRRFS in triple-negative breast cancer (TNBC) patients (p=0.03).
Conclusion
PMRT had a major impact on treatment outcomes in patients with residual lymph nodes following NAC and mastectomy. Among ypN0 patients, PMRT may be beneficial only for those with TNBC.

Citations

Citations to this article as recorded by

Analysis of Individualized Silicone Rubber Bolus Using Fan Beam Computed Tomography in Postmastectomy Radiotherapy: A Dosimetric Evaluation and Skin Acute Radiation Dermatitis Survey
Xue-mei Chen, Chen-di Xu, Li-ping Zeng, Xiao-tong Huang, Ao-qiang Chen, Lu Liu, Liu-wen Lin, Le-cheng Jia, Hua Li, Xiao-bo Jiang
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Oncological outcomes of stage I–II breast cancer treatment after subcutaneous/skin-sparing mastectomies with reconstruction
E. A. Rasskazova, A. D. Zikiryakhodzhaev
MD-Onco.2024; 4(3): 37. CrossRef
Effectiveness of mat pilates on fatigue in women with breast cancer submitted to adjuvant radiotherapy: randomized controlled clinical trial
Daniele Medeiros Torres, Kelly de Menezes Fireman, Erica Alves Nogueira Fabro, Luiz Claudio Santos Thuler, Rosalina Jorge Koifman, Anke Bergmann, Sabrina da Silva Santos
Supportive Care in Cancer.2023;[Epub] CrossRef
The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review
Giulia Ferrarazzo, Alberto Nieri, Emma Firpo, Andrea Rattaro, Alessandro Mignone, Flavio Guasone, Augusto Manzara, Giuseppe Perniciaro, Stefano Spinaci
Current Oncology.2023; 30(10): 8703. CrossRef

5,639 View
212 Download
5 Web of Science
5 Crossref

Postmastectomy Radiation Therapy for Node-Negative Breast Cancer of 5 cm or Larger Tumors: A Multicenter Retrospective Analysis (KROG 20-03): Kyubo Kim, Jinhong Jung, Haeyoung Kim, Wonguen Jung, Kyung Hwan Shin, Ji Hyun Chang, Su Ssan Kim, Won Park, Jee Suk Chang, Yong Bae Kim, Sung Ja Ahn, Ik Jae Lee, Jong Hoon Lee, Hae Jin Park, Jihye Cha, Juree Kim, Jin Hwa Choi, Taeryool Koo, Jeanny Kwon, Jin Hee Kim, Mi Young Kim, Shin-Hyung Park, Yeon-Joo Kim; Cancer Res Treat. 2022;54(2):497-504. Published online August 25, 2021; DOI: https://doi.org/10.4143/crt.2021.933

Abstract PDF PubReader ePub

Purpose
To evaluate the role of postmastectomy radiation therapy (PMRT) in patients with node-negative breast cancer of 5cm or larger tumors undergoing mastectomy
Materials and Methods
Medical records of 274 patients from 18 institutions treated with mastectomy between January 2000 and December 2016 were retrospectively reviewed. Among these, 202 patients underwent PMRT, while 72 did not. Two hundred and forty-one patients (88.0%) received systemic chemotherapy, and 172 (62.8%) received hormonal therapy. Patients receiving PMRT were younger, more likely to have progesterone receptor-positive tumors, and received adjuvant chemotherapy more frequently compared with those without PMRT (p <0.001, 0.018, and <0.001, respectively). Other characteristics were not significantly different between the two groups.
Results
With a median follow-up of 95 months (range, 1-249), there were 9 locoregional recurrences, and 20 distant metastases. The 8-year locoregional recurrence-free survival rates were 98.0% with PMRT and 91.3% without PMRT (p=0.133), and the 8-year disease-free survival (DFS) rates were 91.8% with PMRT and 73.9% without PMRT (p=0.008). On multivariate analysis incorporating age, histologic grade, lymphovascular invasion, hormonal therapy, chemotherapy, and PMRT, the absence of lymphovascular invasion and the receipt of PMRT were associated with improved DFS (p=0.025 and 0.009, respectively).
Conclusion
Locoregional recurrence rate was very low in node-negative breast cancer of 5cm or larger tumors treated with mastectomy regardless of the receipt of PMRT. However, PMRT was significantly associated with improved DFS. Further investigation is needed to confirm these findings.

Citations

Citations to this article as recorded by

Outcomes with and without postmastectomy radiotherapy for pT3N0‐1M0 breast cancer: An institutional experience
Xinxin Rao, Xuanyi Wang, Kairui Jin, Yilan Yang, Xu Zhao, Zhe Pan, Weiluo Lv, Zhen Zhang, Li Zhang, Xiaoli Yu, Xiaomao Guo
Cancer Medicine.2024;[Epub] CrossRef
The effect of radiotherapy on patients with pathological stage IIB breast cancer after breast-conserving surgery or mastectomy: A cohort study
Yi-Ying Pan, Tzu-Yu Lai, Cheng-Ying Shiau, Ling-Ming Tseng, I-Chun Lai, Yu-Ming Liu, Pin-I Huang
Journal of the Chinese Medical Association.2024; 87(2): 202. CrossRef
Post-mastectomy radiation therapy after breast reconstruction: from historic dogmas to practical expert agreements based on a large literature review of surgical and radiation therapy considerations
Yazid Belkacemi, Meena S. Moran, Burcu Celet Ozden, Yazan Masannat, Fady Geara, Mohamed Albashir, Nhu Hanh To, Kamel Debbi, Mahmoud El Tamer
Critical Reviews in Oncology/Hematology.2024; 200: 104421. CrossRef
Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer
Ke Liu, Jia-Yi Li, Guan-Qiao Li, Zhen-Yu He, San-Gang Wu
Expert Review of Anticancer Therapy.2024; 24(12): 1283. CrossRef
Post-Mastectomy Radiation Therapy: Applications and Advancements
Jessica L. Thompson, Steven G. Allen, Cecilia Pesavento, Corey W. Speers, Jacqueline S. Jeruss
Current Breast Cancer Reports.2022; 14(3): 75. CrossRef

6,942 View
203 Download
5 Crossref

General

Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis: Bum-Sup Jang, Ji-Hyun Chang, Seung Hyuck Jeon, Myung Geun Song, Kyung-Hun Lee, Seock-Ah Im, Jong-Il Kim, Tae-You Kim, Eui Kyu Chie; Cancer Res Treat. 2022;54(2):383-395. Published online August 24, 2021; DOI: https://doi.org/10.4143/crt.2021.759

Abstract PDF Supplementary Material PubReader ePub

Purpose
The value of the genomic profiling by targeted gene-sequencing on radiation therapy response prediction was evaluated through integrated analysis including clinical information. Radiation response prediction model was constructed based on the analyzed findings.
Materials and Methods
Patients who had the tumor sequenced using institutional cancer panel after informed consent and received radiotherapy for the measurable disease served as the target cohort. Patients with irradiated tumor locally controlled for more than 6 months after radiotherapy were defined as the durable local control (DLC) group, otherwise, non-durable local control (NDLC) group. Significant genomic factors and domain knowledge were used to develop the Bayesian Network model to predict radiotherapy response.
Results
Altogether, 88 patients were collected for analysis. Of those, 41 (43.6%) and 47 (54.4%) patients were classified as the NDLC and DLC group, respectively. Somatic mutations of NOTCH2 and BCL were enriched in the NDLC group, whereas, mutations of CHEK2, MSH2, and NOTCH1 were more frequently found in the DLC group. Altered DNA repair pathway was associated with better local failure–free survival (hazard ratio, 0.40; 95% confidence interval, 0.19 to 0.86; p=0.014). Smoking somatic signature was found more frequently in the DLC group. Area under the receiver operating characteristic curve of the Bayesian network model predicting probability of 6-month local control was 0.83.
Conclusion
Durable radiation response was associated with alterations of DNA repair pathway and smoking somatic signature. Bayesian network model could provide helpful insights for high precision radiotherapy. However, these findings should be verified in prospective cohort for further individualization.

Citations

Citations to this article as recorded by

Estimating the risk and benefit of radiation therapy in (y)pN1 stage breast cancer patients: A Bayesian network model incorporating expert knowledge (KROG 22–13)
Bum-Sup Jang, Seok-Joo Chun, Hyeon Seok Choi, Ji Hyun Chang, Kyung Hwan Shin
Computer Methods and Programs in Biomedicine.2024; 245: 108049. CrossRef
Prediction of Overall Disease Burden in (y)pN1 Breast Cancer Using Knowledge-Based Machine Learning Model
Seok-Joo Chun, Bum-Sup Jang, Hyeon Seok Choi, Ji Hyun Chang, Kyung Hwan Shin
Cancers.2024; 16(8): 1494. CrossRef
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
I-Shiow Jan, Hui Ju Ch’ang
Radiation Oncology.2023;[Epub] CrossRef
Characterization of the gene signature correlated with favorable response to chemoradiotherapy in rectal cancer: A hypothesis‐generating study
Seung Hyuck Jeon, Eui Kyu Chie
Cancer Medicine.2023; 12(7): 8981. CrossRef
Krüppel-like Factor 10 as a Prognostic and Predictive Biomarker of Radiotherapy in Pancreatic Adenocarcinoma
Yi-Chih Tsai, Min-Chieh Hsin, Rui-Jun Liu, Ting-Wei Li, Hui-Ju Ch’ang
Cancers.2023; 15(21): 5212. CrossRef

5,677 View
181 Download
5 Web of Science
5 Crossref

Head and Neck Cancer

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12: Yun-Gyoo Lee, Hyun Chang, Bhumsuk Keam, Sang Hoon Chun, Jihyun Park, Keon Uk Park, Seong Hoon Shin, Ho Jung An, Kyoung Eun Lee, Keun-Wook Lee, Hye Ryun Kim, Sung-Bae Kim, Myung-Ju Ahn, In Gyu Hwang; Cancer Res Treat. 2021;53(3):671-677. Published online December 7, 2020; DOI: https://doi.org/10.4143/crt.2020.824

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis.
Materials and Methods
We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes.
Results
The patients received anti–programmed cell death protein-1 (PD-1) (n=73, 58%), anti–programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti–PD-1/PD-L1 and anti–cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival.
Conclusion
ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI.

Citations

Citations to this article as recorded by

Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports.2024;[Epub] CrossRef
Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Quan Wang, Xiangzhi Yin, Shengxia Wang, Haijun Lu
Frontiers in Oncology.2024;[Epub] CrossRef
Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma
Dong Hyun Kim, Seo Yoon Jang, Bhumsuk Keam
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2024; 138(6): 763. CrossRef
Neutrophil‐to‐Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma
Angeline A. Truong, Rex H. Lee, Xin Wu, Alain P. Algazi, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, William R. Ryan, Yena Jeon, Mi‐Ok Kim, Patrick K. Ha, Katherine C. Wai
Otolaryngology–Head and Neck Surgery.2024;[Epub] CrossRef
Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
Piero Giuseppe Meliante, Federica Zoccali, Marco de Vincentiis, Massimo Ralli, Carla Petrella, Marco Fiore, Antonio Minni, Christian Barbato
Diagnostics.2023; 13(5): 862. CrossRef
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols
Catherine T. Haring, Lulia A. Kana, Sarah M. Dermody, Collin Brummel, Jonathan B. McHugh, Keith A. Casper, Steven B. Chinn, Kelly M. Malloy, Michelle Mierzwa, Mark E. P. Prince, Andrew J. Rosko, Jennifer Shah, Chaz L. Stucken, Andrew G. Shuman, J. Chad Br
Cancer.2023; 129(18): 2817. CrossRef
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, Constantin Volovăț, Simona Ruxandra Volovăț, Dragoș Teodor Petru Iancu, Roxana Irina Iancu, Florinel Bădulescu
Diagnostics.2023; 13(16): 2620. CrossRef
Integrating Cutting-Edge Methods to Oral Cancer Screening, Analysis, and Prognosis
Sagar Dholariya, Ragini D. Singh, Amit Sonagra, Dharamveer Yadav, Bhairavi N. Vajaria, Deepak Parchwani
Critical Reviews™ in Oncogenesis.2023; 28(2): 11. CrossRef
Neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Tibera K. Rugambwa, Omar Abdihamid, Xiangyang Zhang, Yinghui Peng, Changjing Cai, Hong Shen, Shan Zeng, Wei Qiu
Frontiers in Oncology.2023;[Epub] CrossRef
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Surviva
Khalil Choucair, Caroline Nebhan, Alessio Cortellini, Stijn Hentzen, Yinghong Wang, Cynthia Liu, Raffaele Giusti, Marco Filetti, Paolo Antonio Ascierto, Vito Vanella, Domenico Galetta, Annamaria Catino, Nour Al-Bzour, Azhar Saeed, Ludimila Cavalcante, Pam
Cancers.2023; 15(20): 5052. CrossRef
A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors
Dengxiong Kang, Siping Liu, Xin Yuan, Shenxiang Liu, Zhengrong Zhang, Zhilian He, Xudong Yin, Haiyan Mao
Journal of Cancer Research and Clinical Oncology.2023; 149(20): 18215. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients
Jun-Liang Li, Tsai-Ling Hsieh, Ming-Che Ou, Frank Cheau-Feng Lin, Stella Chin-Shaw Tsai
Oral Oncology.2022; 126: 105729. CrossRef
Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis
Yukinori Takenaka, Ryohei Oya, Norihiko Takemoto, Hidenori Inohara
Head & Neck.2022; 44(5): 1237. CrossRef
Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
Maria A. Lopez-Olivo, Valeria Valerio, Aliza R. Karpes Matusevich, Marianela Brizio, Michelle Kwok, Yimin Geng, Maria E. Suarez-Almazor, Ines Colmegna
Vaccines.2022; 10(8): 1195. CrossRef
Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma
Xueying Wang, Kui Cao, Erliang Guo, Xionghui Mao, Lunhua Guo, Cong Zhang, Junnan Guo, Gang Wang, Xianguang Yang, Ji Sun, Susheng Miao
Frontiers in Immunology.2021;[Epub] CrossRef
Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma
Xing-xing Huo, Shu-jie Wang, Hang Song, Ming-de Li, Hua Yu, Meng Wang, Hong-xiao Gong, Xiao-ting Qiu, Yong-fu Zhu, Jian-ye Zhang
Frontiers in Pharmacology.2021;[Epub] CrossRef

7,332 View
225 Download
17 Web of Science
17 Crossref

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma: Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim; Cancer Res Treat. 2019;51(1):300-312. Published online May 9, 2018; DOI: https://doi.org/10.4143/crt.2018.012

Abstract PDF Supplementary Material PubReader ePub

Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.

Citations

Citations to this article as recorded by

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
Journal of Clinical Oncology.2024; 42(5): 507. CrossRef
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
Cancer Research and Treatment.2024; 56(1): 37. CrossRef
Extracellular vesicles as tools and targets in therapy for diseases
Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports.2024;[Epub] CrossRef
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
Biomolecules.2024; 14(8): 925. CrossRef
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
Frontiers in Oncology.2024;[Epub] CrossRef
Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
Virchows Archiv.2024; 485(6): 965. CrossRef
FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
Scientific Reports.2023;[Epub] CrossRef
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
OncoImmunology.2023;[Epub] CrossRef
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
Biomedicines.2023; 12(1): 24. CrossRef
New Treatment Development for Larynx Preservation
Susumu Okano
Koutou (THE LARYNX JAPAN).2023; 35(2): 98. CrossRef
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
Current Treatment Options in Oncology.2022; 23(2): 254. CrossRef
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
Frontiers in Immunology.2022;[Epub] CrossRef
Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
Diagnostics.2022; 12(5): 1071. CrossRef
Unraveling most abundant mutational signatures in head and neck cancer
Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
International Journal of Cancer.2021; 148(1): 115. CrossRef
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
Critical Reviews in Oncology/Hematology.2021; 160: 103284. CrossRef
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
Cancers.2021; 13(7): 1714. CrossRef
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
Processes.2021; 9(5): 792. CrossRef
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
International Journal of Molecular Sciences.2021; 22(9): 4981. CrossRef
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Cancer Medicine.2021; 10(20): 7012. CrossRef
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
Journal of Clinical Investigation.2021;[Epub] CrossRef
Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
Applied Sciences.2021; 11(24): 12079. CrossRef
Immunologic and immunogenomic aspects of tumor progression
Andrea Ladányi, József Tímár
Seminars in Cancer Biology.2020; 60: 249. CrossRef
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
Medical Oncology.2020;[Epub] CrossRef
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
Frontiers in Oncology.2020;[Epub] CrossRef
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
British Journal of Cancer.2020; 122(11): 1649. CrossRef
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
BMC Cancer.2020;[Epub] CrossRef
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
Scientific Reports.2020;[Epub] CrossRef
Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
Cancers.2020; 12(7): 1777. CrossRef
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
British Journal of Cancer.2020; 123(12): 1720. CrossRef
Mutationssignaturen beim Kopf- und Hals-Tumor
M. Plath, J. Hess, K. Zaoui
HNO.2020; 68(12): 922. CrossRef
BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
Hein Chun, Sangwoo Kim, Inanc Birol
Bioinformatics.2019; 35(22): 4806. CrossRef
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
Frontiers in Oncology.2019;[Epub] CrossRef
A Review of HPV-Related Head and Neck Cancer
Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
Journal of Clinical Medicine.2018; 7(9): 241. CrossRef

15,198 View
649 Download
35 Web of Science
35 Crossref

BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database: Ki-Tae Hwang, Kwangsoo Kim, Ji Hyun Chang, Sohee Oh, Young A Kim, Jong Yoon Lee, Se Hee Jung, In Sil Choi; Cancer Res Treat. 2018;50(3):658-669. Published online July 4, 2017; DOI: https://doi.org/10.4143/crt.2017.134

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated B-cell lymphoma 2 (BCL2) regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database.
Materials and Methods
We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA-seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data.
Results
The luminal A and luminal B subtypes showed upregulated expression of RPPA and mRNAseq and hypomethylation compared to the human epidermal growth factor receptor 2 (HER2) and triple-negative subtypes (all p < 0.001). No mutations were found in any subjects. High mRNA-seq and high RPPA were strongly associated with positive estrogen receptor, positive progesterone receptor (all p < 0.001), and negative HER2 (p < 0.001 and p=0.002, respectively). Correlation analysis revealed a strong positive correlation between protein and mRNA levels and a strong negative correlation between methylation and protein and mRNA levels (all p < 0.001). The high BCL2 group showed superior overall survival compared to the low BCL2 group (p=0.006).
Conclusion
The regulation of BCL2 was mainly associated with methylation across the molecular subtypes of breast cancer, and luminal A and luminal B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with superior prognosis than downregulation of BCL2.

Citations

Citations to this article as recorded by

AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen
Maiquidieli Dal Berto, Laura Martin Manfroi, Aniúsca Vieira dos Santos, Giovana Tavares dos Santos, Gabriela Krüger da Costa, Camila Macedo Boaro, Péttala Rigon, Rafael José Vargas Alves, Claudia Giuliano Bica
Advances in Cancer Biology - Metastasis.2023; 8: 100108. CrossRef
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Xin Yang, Yao Li, Xu lu, Xiaotian Ren, Bin Hua
BMC Cancer.2023;[Epub] CrossRef
Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature
Guang‐Li Zhu, Kai‐Bin Yang, Cheng Xu, Rui‐Jia Feng, Wen‐Fei Li, Jun Ma
Cancer Medicine.2022; 11(23): 4673. CrossRef
Significance of Bcl-2 expression in breast cancer
Nitika Kumari, Natarajan Suresh, Josephine A.
Biomedicine.2022; 42(4): 775. CrossRef
Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers
Yingying Xu, Yonghao Liang, Guanghao Yin
Clinical and Translational Oncology.2022; 25(4): 1024. CrossRef
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
Lorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, Sofia Asioli, Giordano Nicoletti, Veronica Giusti, Francesca Ruzzi, Marianna L. Ianzano, Laura Scalambra, Roberta Laranga, Tania Balboni, Maddalena Arigoni, Martina Olivero, Raffaele A. Calogero, Car
Scientific Reports.2021;[Epub] CrossRef
Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
Ki-Tae Hwang, Young A. Kim, Jongjin Kim, Hyeon Jeong Oh, Jeong Hwan Park, In Sil Choi, Jin Hyun Park, Sohee Oh, Ajung Chu, Jong Yoon Lee, Kyu Ri Hwang
Scientific Reports.2021;[Epub] CrossRef
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study
Alessandra Fabi, Marcella Mottolese, Anna Di Benedetto, Francesca Sperati, Cristiana Ercolani, Simonetta Buglioni, Cecilia Nisticò, Gianluigi Ferretti, Patrizia Vici, Letizia Perracchio, Paola Malaguti, Michelangelo Russillo, Claudio Botti, Edoardo Pescar
Clinical Breast Cancer.2020; 20(6): e761. CrossRef
Methylation of the NT5E Gene Is Associated with Poor Prognostic Factors in Breast Cancer
Young Ju Jeong, Hoon Kyu Oh, Hye Ryeon Choi, Sung Hwan Park
Diagnostics.2020; 10(11): 939. CrossRef
Differential responses of epithelial cells from urinary and biliary tract to eggs of Schistosoma haematobium and S. mansoni
Rafael Nacif-Pimenta, Alessandra da Silva Orfanó, Ilana A. Mosley, Shannon E. Karinshak, Kenji Ishida, Victoria H. Mann, Paulo Marcos Zech Coelho, José M. Correia da Costa, Michael H. Hsieh, Paul J. Brindley, Gabriel Rinaldi
Scientific Reports.2019;[Epub] CrossRef
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
Hariprasad Thangavel, Carmine De Angelis, Suhas Vasaikar, Raksha Bhat, Mohit Kumar Jolly, Chandandeep Nagi, Chad J. Creighton, Fengju Chen, Lacey E. Dobrolecki, Jason T. George, Tanya Kumar, Noor Mazin Abdulkareem, Sufeng Mao, Agostina Nardone, Mothaffar
Journal of Clinical Medicine.2019; 8(11): 1772. CrossRef
BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer
Athina Kladi-Skandali, Diamantis C. Sideris, Andreas Scorilas
Clinical Chemistry and Laboratory Medicine (CCLM).2018; 57(2): 276. CrossRef

15,710 View
330 Download
13 Web of Science
12 Crossref

Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea: Sanghyuk Song, Ji Hyun Chang, Hak Jae Kim, Yeon Sil Kim, Jin Hee Kim, Yong Chan Ahn, Jae-Sung Kim, Si Yeol Song, Sung Ho Moon, Moon June Cho, Seon Min Youn; Cancer Res Treat. 2017;49(3):688-694. Published online October 31, 2016; DOI: https://doi.org/10.4143/crt.2016.219

Abstract PDF Supplementary Material PubReader ePub

Purpose
Stereotactic ablative radiotherapy (SABR) is an effective emerging technique for early-stage non-small cell lung cancer (NSCLC). We investigated the current practice of SABR for early-stage NSCLC in Korea.
Materials and Methods
We conducted a nationwide survey of SABR for NSCLC by sending e-mails to all board-certified members of the Korean Society for Radiation Oncology. The survey included 23 questions focusing on the technical aspects of SABR and 18 questions seeking the participants’ opinions on specific clinical scenarios in the use of SABR for early-stage NSCLC. Overall, 79 radiation oncologists at 61/85 specialist hospitals in Korea (71.8%) responded to the survey.
Results
SABR was used at 33 institutions (54%) to treat NSCLC. Regarding technical aspects, the most common planning methods were the rotational intensity-modulated technique (59%) and the static intensity-modulated technique (49%). Respiratory motion was managed by gating (54%) or abdominal compression (51%), and 86% of the planning scans were obtained using 4-dimensional computed tomography. In the clinical scenarios, the most commonly chosen fractionation schedule for peripherally located T1 NSCLC was 60 Gy in four fractions. For centrally located tumors and T2 NSCLC, the oncologists tended to avoid SABR for radiotherapy, and extended the fractionation schedule.
Conclusion
The results of our survey indicated that SABR is increasingly being used to treat NSCLC in Korea. However, there were wide variations in the technical protocols and fractionation schedules of SABR for early-stage NSCLC among institutions. Standardization of SABR is necessary before implementing nationwide, multicenter, randomized studies.

Citations

Citations to this article as recorded by

Guidelines for safe practice of stereotactic body (ablative) radiation therapy: RANZCR 2023 update
Howard Yu‐hao Liu, Nicholas Hardcastle, Michael Bailey, Shankar Siva, Anna Seeley, Tamara Barry, Jeremy Booth, Louis Lao, Michelle Roach, Stacey Buxton, David Thwaites, Matthew Foote
Journal of Medical Imaging and Radiation Oncology.2024; 68(2): 217. CrossRef
Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease
Sophia C. Kamran, David Palma, Matthew S. Katz, Anthony L. Zietman
Seminars in Radiation Oncology.2021; 31(3): 200. CrossRef
MiR-223-3p regulates cell viability, migration, invasion, and apoptosis of non-small cell lung cancer cells by targeting RHOB
Shufang Li, Yuping Feng, Yuxia Huang, Yu Liu, Yanxi Wang, Yan Liang, Hui Zeng, Hong Qu, Ling Wei
Open Life Sciences.2020; 15(1): 389. CrossRef

9,904 View
235 Download
3 Web of Science
3 Crossref

Radiation-Induced Sarcoma: A 15-Year Experience in a Single Large Tertiary Referral Center: Kyung Su Kim, Ji Hyun Chang, Noorie Choi, Han-Soo Kim, Ilkyu Han, Kyung Chul Moon, Il Han Kim, Hak Jae Kim; Cancer Res Treat. 2016;48(2):650-657. Published online September 9, 2015; DOI: https://doi.org/10.4143/crt.2015.171

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to report on the incidence and the experience in management of radiation-induced sarcoma (RIS) at a large single center in Korea for 15 years.
Materials and Methods
We retrospectively reviewed the sarcoma registry of a large institution from January 2000 to April 2014.
Results
Out of the 3,674 patients listed in the registry, 33 patients (0.9%) diagnosed with RIS were identified. The median latency of RIS was 12.1 years. The number of cases of RIS increased from four cases in the years 2000-2003 to 14 cases in the years 2012-2014. The most common histology was osteosarcoma (36.4%). The median follow-up period was 23.1 months, the median overall survival (OS) of all patients was 2.9 years, and their 5-year survival rate was 44.7%. Univariate and multivariate analyses showed association of the age at diagnosis (p=0.01) and the treatment aim (p=0.001) with the OS. The median OS and the 5-year survival rate of patients treated with curative surgery (n=19) were 9.6 years and 65%, respectively, and of the conservatively treated patients, 0.7 years and 0% (n=14). Re-irradiation was delivered to nine patients, and radiation toxicity was observed in five patients.
Conclusion
In this study, RIS accounted for 0.9% of the cases of sarcoma, with increasing incidence. Despite the association of curative resection with increased survival, it could be applied to only 58% of the patients. Considering the limited treatment options for RIS, conduct of a genetic study to identify the underlying mechanism of RIS is needed.

Citations

Citations to this article as recorded by

A bone tumor‐like chest wall mass lesion with pathological rib fractures observed 13 years after lung stereotactic body radiotherapy: A case report
Masaki Matsuda, Jiro Ichikawa, Takafumi Komiyama, Kojiro Onohara, Masahide Saito, Hikaru Nemoto, Mizuki Kubota, Hiroshi Onishi
Thoracic Cancer.2024; 15(26): 1912. CrossRef
The role of perioperative treatment in radiation-associated soft tissue sarcomas
Konrad Zasadziński, Mateusz Jacek Spałek
Oncologie.2024; 26(6): 1065. CrossRef
Clinical and Pathologic Characterization of 94 Radiation-Associated Sarcomas: Our Institutional Experience
Erica Y. Kao, Abbye E. McEwen, James K. Aden, Stephanie K. Schaub, Robert W. Ricciotti, Jose G. Mantilla
International Journal of Surgical Pathology.2023; 31(5): 532. CrossRef
Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study
Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A. Gupta
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Treatment and Outcomes of Radiation-Induced Soft Tissue Sarcomas of the Extremities and Trunk—A Systematic Review of the Literature
Maria L. Inchaustegui, Kelly Kon-Liao, Kim Ruiz-Arellanos, George Aquilino E. Silva, Marcos R. Gonzalez, Juan Pretell-Mazzini
Cancers.2023; 15(23): 5584. CrossRef
Temporary Knockdown of p53 During Focal Limb Irradiation Increases the Development of Sarcomas
Andrea R. Daniel, Chang Su, Nerissa T. Williams, Zhiguo Li, Jianguo Huang, Omar Lopez, Lixia Luo, Yan Ma, Lorraine da Silva Campos, Sara R. Selitsky, Jennifer L. Modliszewski, Siyao Liu, Rosa Hernansaiz-Ballesteros, Yvonne M. Mowery, Diana M. Cardona, Cha
Cancer Research Communications.2023; 3(12): 2455. CrossRef
Treatment related factors associated with the risk of breast radio-induced-sarcoma
Céline Mirjolet, Ibrahima Diallo, Aurélie Bertaut, Cristina Veres, Paul Sargos, Sylvie Helfre, Marie-Pierre Sunyach, Gilles Truc, Cécile Le Pechoux, Amaury Paumier, Anne Ducassou, Maria Jolnerovski, Juliette Thariat, Michel Lapeyre, Abel Cordoba, Marc-And
Radiotherapy and Oncology.2022; 171: 14. CrossRef
Radiation-induced osteosarcoma in the pubic bone after proton radiotherapy for prostate cancer: a case report
Hiroatsu Nakashima, Tetsuro Takatsu, Reiko Imai
Journal of Rural Medicine.2022; 17(2): 94. CrossRef
Premalignant Conditions of Bone
Michael D. Eckhoff, Matthew E. Wells, Osvaldo Padilla, Elizabeth M. Polfer, Christopher J. Castagno, Ahmed M. Thabet, Shaimaa Elzamly, Harry L. Wilson, Rajiv Rajani
JAAOS: Global Research and Reviews.2022;[Epub] CrossRef
Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma
Edmund K. Bartlett, Avinash Sharma, Kenneth Seier, Cristina R. Antonescu, Narasimhan P. Agaram, Bhumika Jadeja, Evan Rosenbaum, Ping Chi, Murray F. Brennan, Li-Xuan Qin, Kaled M. Alektiar, Samuel Singer
JCO Precision Oncology.2022;[Epub] CrossRef
Radiation-induced soft tissue sarcoma of the neck after radiation therapy for Hodgkin's lymphoma: a clinical case
Nikolai A. Ognerubov, Tatiana S. Antipova
Journal of Modern Oncology.2022; 24(3): 325. CrossRef
Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels
Libo Yang, Dongli Lu, Yutian Lai, Mengjia Shen, Qiuxiao Yu, Ting Lei, Tianjie Pu, Hong Bu
Annals of Surgical Oncology.2021; 28(2): 975. CrossRef
Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review
Andrés Coca-Pelaz, Antti A. Mäkitie, Primož Strojan, June Corry, Avraham Eisbruch, Jonathan J. Beitler, Sandra Nuyts, Robert Smee, Johannes A. Langendijk, William M. Mendenhall, Cesare Piazza, Alessandra Rinaldo, Alfio Ferlito
Advances in Therapy.2021; 38(1): 90. CrossRef
En bloc resection and reconstruction in patients with advanced recurrent nasopharyngeal carcinoma and radiation-induced sarcoma of the head and neck
W.-l. Chen, Y.-M. Liu, B. Zhou, R. Chen, Z.-y. Lin, Z.-q. Huang, Z-x. Huang
International Journal of Oral and Maxillofacial Surgery.2021; 50(6): 711. CrossRef
Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites
Anson Snow, Alexander Ring, Lucas Struycken, Wendy Mack, Melissa Koç, Julie E. Lang
Cancer Epidemiology.2021; 70: 101857. CrossRef
Radiation-Induced Sarcoma: A Retrospective Population-Based Study Over 34 Years in a Single Institution
L.B. Callesen, A. Safwat, H.K. Rose, F.B. Sørensen, T. Baad-Hansen, N. Aggerholm-Pedersen
Clinical Oncology.2021; 33(5): e232. CrossRef
Proliferating trichilemmal tumour of the eyelid in a 7-year-old girl
Avery Bryan, Susan Kurian, Yan Li, Paige Bundrick
BMJ Case Reports.2021; 14(2): e237476. CrossRef
Treating radiation-induced sarcoma of the head and neck: A case report
Yuka Takumi, Kazufumi Obata, Atsushi Kondo, Ryo Miyata, Ayaka Sasaki, Kenichi Takano
Otolaryngology Case Reports.2021; 19: 100283. CrossRef
Pelvic Radiation-Induced Sarcoma With Rhabdomyoblastic Differentiation Following Treatment of Cervical Cancer
Shahd S Almohsen, Hala Alnuaim, Alaa A Salim, Haitham Arabi
Cureus.2021;[Epub] CrossRef
MYC expression has limited utility in the distinction of undifferentiated radiation‐associated sarcomas from sporadic sarcomas and sarcomatoid carcinoma
Jeffrey K Mito, Xiaohua Qian, Vickie Y Jo, Leona A Doyle
Histopathology.2020; 77(4): 667. CrossRef
Sarcomas óseos secundarios
J.-C. Mattei, A. Griffin, P. Ferguson, G. Venton, J. Wunder, A. Rochwerger
EMC - Aparato Locomotor.2020; 53(4): 1. CrossRef
Sarcomes osseux secondaires
J.-C. Mattei, A. Griffin, P. Ferguson, G. Venton, J. Wunder, A. Rochwerger
EMC - Appareil locomoteur.2020; 34(3): 1. CrossRef
Radiation-Associated Sarcomas
Jeffrey K. Mito, Devarati Mitra, Leona A. Doyle
Surgical Pathology Clinics.2019; 12(1): 139. CrossRef
A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas
Jeffrey K. Mito, Devarati Mitra, Constance M. Barysauskas, Adrián Mariño-Enriquez, Elizabeth A. Morgan, Christopher D.M. Fletcher, Chandrajit P. Raut, Elizabeth H. Baldini, Leona A. Doyle
International Journal of Radiation Oncology*Biology*Physics.2019; 104(2): 425. CrossRef
Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries
Christina Eder-Czembirek, Doris Moser, Simone Holawe, Thomas Brodowicz, Jutta Ries, Irene Sulzbacher, Edgar Selzer
Clinics.2019; 74: e701. CrossRef
Multifocal superficial rapidly growing postirradiation sarcoma mimicking metastatic carcinoma
Debasis Gochhait, Priyadarshini Dehuri, Vidhyalakshmi Rangarajan, Neelaiah Siddaraju
Journal of Mid-life Health.2019; 10(2): 101. CrossRef
Radiation-induced sarcoma in a cat following hypofractionated, palliative intent radiation therapy for large-cell lymphoma
Matthew R Cook, Michael P Martinez, Joelle M Fenger, Noopur C Desai
Journal of Feline Medicine and Surgery Open Reports.2019;[Epub] CrossRef
Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma
Richard A. Peterson, Bhavani Kashyap, Pamala A. Pawloski, Anna C. Forsberg, Leah R. Hanson
Case Reports in Oncological Medicine.2019; 2019: 1. CrossRef
Radiation‐associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma
Samuli H. Salminen, Mika M. Sampo, Tom O. Böhling, Laura Tuomikoski, Maija Tarkkanen, Carl P. Blomqvist
Cancer Medicine.2018; 7(9): 4825. CrossRef
Radiation-Associated Sarcoma of the Neck: Case Series and Systematic Review
Lawrence Williams, Lyubov Tmanova, Wojciech K. Mydlarz, Brandi Page, Jeremy D. Richmon, Harry Quon, Nicole C. Schmitt
Annals of Otology, Rhinology & Laryngology.2018; 127(10): 735. CrossRef
Radiation‐associated neoplasia: clinical, pathological and genomic correlates
Lynette M Sholl, Justine A Barletta, Jason L Hornick
Histopathology.2017; 70(1): 70. CrossRef
Magnetic Resonance Imaging of Soft Tissue Masses
Aaron D. Fain, Francesca D. Beaman
Seminars in Roentgenology.2017; 52(4): 227. CrossRef
Characteristics of tumors that have developed in mice injected with syngenic irradiated mesenchymal stem cells of bone marrow
E. Yu. Moskaleva, E. S. Zhorova, Yu. P. Semochkina, A. V. Rodina, O. V. Vysotskaya, A. I. Glukhov, A. A. Chukalova, G. A. Posypanova, V. P. Saprykin
Cell and Tissue Biology.2017; 11(5): 381. CrossRef
Case Report: Primary De Novo Sarcoma In Transplant Pancreas Allograft
S. Nagaraju, S.J. Grethlein, S. Vaishnav, A.A. Sharfuddin, J.A. Powelson, J.A. Fridell
Transplantation Proceedings.2017; 49(10): 2352. CrossRef
Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma
Lie-Qiang Liao, Hong-Hong Yan, Jun-Hao Mai, Wei-Wei Liu, Hao Li, Zhu-Ming Guo, Zong-Yuan Zeng, Xue-Kui Liu
Chinese Journal of Cancer.2016;[Epub] CrossRef

13,847 View
196 Download
28 Web of Science
35 Crossref

p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines: Sung-Ung Moon, Jin Won Kim, Ji Hea Sung, Mi Hyun Kang, Se-Hyun Kim, Hyun Chang, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee; Cancer Res Treat. 2015;47(3):501-508. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2014.054

Abstract PDF PubReader ePub

Purpose
p21-activated kinases (PAKs) are involved in cytoskeletal reorganization, gene transcription, cell proliferation and survival, and oncogenic transformation. Therefore, we hypothesized that PAK expression levels could predict the sensitivity of pancreatic cancer cells to gemcitabine treatment, and PAKs could be therapeutic targets.
Materials and Methods
Cell viability inhibition by gemcitabine was evaluated in human pancreatic cancer cell lines (Capan-1, Capan-2, MIA PaCa-2, PANC-1, Aspc-1, SNU-213, and SNU-410). Protein expression and mRNA of molecules was detected by immunoblot analysis and reverse transcription polymerase chain reaction. To define the function of PAK4, PAK4 was controlled using PAK4 siRNA.
Results
Capan-2, PANC-1, and SNU-410 cells were resistant to gemcitabine treatment. Immunoblot analysis of signaling molecules reported to indicate gemcitabine sensitivity showed higher expression of PAK4 and lower expression of human equilibrative nucleoside transporter 1 (hENT1), a well-known predictive marker for gemcitabine activity, in the resistant cell lines. Knockdown of PAK4 using siRNA induced the upregulation of hENT1. In resistant cell lines (Capan-2, PANC-1, and SNU-410), knockdown of PAK4 by siRNA resulted in restoration of sensitivity to gemcitabine.
Conclusion
PAK4 could be a predictive marker of gemcitabine sensitivity and a potential therapeutic target to increase gemcitabine sensitivity in pancreatic cancer.

Citations

Citations to this article as recorded by

Biological role of the PAK4 signaling pathway: A prospective therapeutic target for multivarious cancers
Md. Mozibullah, Md. Junaid
Arabian Journal of Chemistry.2023; 16(1): 104438. CrossRef
Expression Patterns of PAK4 and PHF8 Are Associated with the Survival of Gallbladder Carcinoma Patients
Ae Ri Ahn, Maryam Karamikheirabad, Min Su Park, Junyue Zhang, Hyun Sun Kim, Ji Su Jeong, Kyoung Min Kim, Ho Sung Park, Kyu Yun Jang
Diagnostics.2023; 13(6): 1149. CrossRef
PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways
Charudatt Samant, Ramesh Kale, Anand Bokare, Mahip Verma, K. Sreedhara Ranganath Pai, Mandar Bhonde
Biochemistry and Biophysics Reports.2023; 35: 101544. CrossRef
A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine
Hong He, Chelsea Dumesny, Ching-Seng Ang, Li Dong, Yi Ma, Jun Zeng, Mehrdad Nikfarjam
Translational Oncology.2022; 16: 101329. CrossRef
Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors
Cong Wang, Jiawei Xia, Yan Lei, Rui Lu, Mingliang Zhang, He Lv, Qianqian Hong, Tao Lu, Yadong Chen, Hongmei Li
Bioorganic & Medicinal Chemistry.2022; 60: 116700. CrossRef
A Study on the Effect of the Substituent against PAK4 Inhibition Using In Silico Methods
Hye Ree Yoon, Chong Chul Chai, Cheol Hee Kim, Nam Sook Kang
International Journal of Molecular Sciences.2022; 23(6): 3337. CrossRef
Alloferon Affects the Chemosensitivity of Pancreatic Cancer by Regulating the Expression of SLC6A14
Hyejung Jo, Dahae Lee, Cheolhyeon Go, Yoojin Jang, Suhyun Bae, Tomoyo Agura, Jiye Hong, Dongmin Kang, Yejin Kim, Jae Seung Kang
Biomedicines.2022; 10(5): 1113. CrossRef
The significance of PAK4 in signaling and clinicopathology: A review
Xinbo Yu, Changwei Huang, Jiyuan Liu, Xinyu Shi, Xiaodong Li
Open Life Sciences.2022; 17(1): 586. CrossRef
The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma
Yi Ma, Mehrdad Nikfarjam, Hong He
Cancer Letters.2022; 548: 215868. CrossRef
p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond
Xiaodong Li, Feng Li
Cancers.2022; 14(19): 4736. CrossRef
Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment
Lizhou Xu, Farid N. Faruqu, Yau M. Lim, Kee Y. Lim, Revadee Liam-Or, Adam A. Walters, Paul Lavender, David Fear, Claire M. Wells, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
Biomaterials.2021; 264: 120369. CrossRef
RETRACTED ARTICLE: Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression
Shasha Bi, Yan Wang, Hu Feng, Qingchang Li
Cell Cycle.2020; 19(7): 801. CrossRef
p21-Activated Kinases in Thyroid Cancer
Luis Bautista, Christina M Knippler, Matthew D Ringel
Endocrinology.2020;[Epub] CrossRef
Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases
Rakesh Kumar, Aswathy Mary Paul, Ravikumar Amjesh, Bijesh George, M. Radhakrishna Pillai
Cancer and Metastasis Reviews.2020; 39(3): 583. CrossRef
Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer
Kai Wang, Graham S. Baldwin, Mehrdad Nikfarjam, Hong He
American Journal of Physiology-Gastrointestinal and Liver Physiology.2019; 316(5): G632. CrossRef
PAK4 Pathway as a Potential Therapeutic Target in Pancreatic Cancer
Kiruthikah Thillai, Debashis Sarker, Claire Wells
Future Oncology.2018; 14(7): 579. CrossRef
p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation
Kai Wang, Graham S Baldwin, Mehrdad Nikfarjam, Hong He
World Journal of Gastroenterology.2018; 24(33): 3709. CrossRef
Structure, biochemistry, and biology of PAK kinases
Rakesh Kumar, Rahul Sanawar, Xiaodong Li, Feng Li
Gene.2017; 605: 20. CrossRef
Prognostic value of p21‐activated kinase 4 in resected pancreatic cancer
Sehhoon Park, Jin Won Kim, Haeryoung Kim, Ji‐Won Kim, Yu Jung Kim, Keun‐Wook Lee, Jee Hyun Kim, Jai Hwan Kim, Jin‐Hyeok Hwang, Young Rok Choi, Jai Young Cho, Yoo‐Seok Yoon, Ho‐Seong Han
APMIS.2017; 125(8): 699. CrossRef
Pdx1-Cre-driven conditional gene depletion suggests PAK4 as dispensable for mouse pancreas development
Miao Zhao, Parisa Rabieifar, Tânia D. F. Costa, Ting Zhuang, Audrey Minden, Matthias Löhr, Rainer Heuchel, Staffan Strömblad
Scientific Reports.2017;[Epub] CrossRef
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine
Kai Wang, Nhi Huynh, Xiao Wang, Graham Baldwin, Mehrdad Nikfarjam, Hong He
International Journal of Oncology.2017;[Epub] CrossRef
S-1 plus nab -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model
Masaya Suenaga, Suguru Yamada, Tsutomu Fujii, Chie Tanaka, Mitsuro Kanda, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
Journal of Surgical Oncology.2016; 113(4): 413. CrossRef
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
Dannel Yeo, Hong He, Oneel Patel, Andrew M. Lowy, Graham S. Baldwin, Mehrdad Nikfarjam
BMC Cancer.2016;[Epub] CrossRef
PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway
Xiang-Rong Shu, Jing Wu, He Sun, Li-Qun Chi, Jin-Huan Wang
Diagnostic Pathology.2015;[Epub] CrossRef

16,152 View
185 Download
33 Web of Science
24 Crossref

Case Report

Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports: Jong Keun Lim, Joong Bae Ahn, Sung Ha Cheon, Hyun Chang, Jong Yul Jung, Sun Young Rha, Jae Kyung Roh, Sung Hoon Noh, Ho Geun Kim, Hyun Cheol Chung, Hei-Cheul Jeung; Cancer Res Treat. 2006;38(3):184-188. Published online June 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.3.184

Abstract PDF PubReader ePub

Surgical resection of colorectal cancer metastasis to the liver results in a 5-year survival rate of around 40%. Liver metastasis from other cancers such as neuroendocrine carcinoma and genitourinary tumors are also treated effectively with combined liver resection. However, hepatic metastasectomy for liver tumor from gastric cancer hasn't been considered as a standard treatment, and the benefit for this treatment has not been established. We report here on two cases of gastrectomy and combined liver resection for synchronous liver metastasis without any evidence of other metastatic lesions, and these two patients have survived for more than 7 years without evidence of disease recurrence. In conclusion, for patients with hepatic metastasis from gastric cancer, combined surgical resection of the liver metastasis should be considered as a treatment option when metastasis to other sites can be excluded.

Citations

Citations to this article as recorded by

Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer
Guo-Liang Yao
World Journal of Gastroenterology.2015; 21(9): 2754. CrossRef

9,014 View
73 Download
1 Crossref

Original Articles

The immunological characteristics of tumor infiltrating lymphocytes and tumor draining lymph node lymphocytes in advanced stomach cancer: Jae Yong Lee, Jung Soon Jang, Young Iee Park, Noe Kyeong Kim, Chee Young Choe, Woo Ho Kim, Chul Woo Kim, Young Il Kim, Dae Seog Heo, Woo Hyun Chang; J Korean Cancer Assoc. 1992;24(5):656-665.

Abstract PDF: No abstract available.

2,302 View
20 Download

Heterotransplantation of Cell Line ( SS-I ) derived from Human Stomach Adenocarcinoma in Athymic Nude Mice: Jin Pok Kim, Jae Gahb Park, Han Kwang Yang, ng Yong Cha, Shin Yong Moon, Woo Ho Kim, Yong Il Kim, Woo Hyun Chang, Mun Ho Lee; J Korean Cancer Assoc. 1984;16(2):229-233.

Abstract PDF: The result of subcutaneous inoculation of SS-1(Seoul National University, Adenocarcinoma of the Stomach) cell line"' into nude mice is described Three million SS-I cells from passage 29 were injected subcutaneously into the subscapular area of a 57-day-old male nude mouse. But tumor was not produced. Twenty million and one hundred thousand SS-I cells from passage 35-37 were injected into a 27-day-old male nude mouse. After eight days seven million and eight hundred SS-I cells from pasaage 39-40 were injected again into the same site of the mouse. Nineteen days after initial injection: a.tumor became visible at the site of inoculation. After 53 days, the nude mouse died due to wasting by the huge tumor. Sixty-six million SS-I cells from passage 42-45 were injected into a 26-day-old male nude mouae. After 18 days a tumor became visible and it grew fast. After 53 days the tumor measured. 20.8 x 20. 1 x 15.0 mm and the tumot was subpassed to a 21-day-old male nude mouse. After 58days from the first subpassage the.' tumor measured 26. 4 x 22. 4 x 12. 5 mm and the tumor was subpassed again to a 44-day-old male nude mouse. Doubling time of the tumor was about 5.5 days. Histopathalogically the tumors produced in nude mice. were similar to the human tumor of arigin.

2,728 View
14 Download

Human Colon Carcinoma Transplanted into Nude Mouse: Jae Gahb Park, Han Kwang Yang, Jin Pek Kim, Woo Ho Kim, Yong Il Kim, Woo Hyun Chang, Mun Ho Lee; J Korean Cancer Assoc. 1985;17(1):1-10.

Abstract PDF: Since April 1984, we have transplanted 10 human adenocarcinomas to BALB/c nude mice and subcutaneous growth was obtained with 5 tumors. Two tumors were lost during 1st passage and 2nd passage due to accidental death of tumor bearing nude mice. Now SCN-1, SCN-2 and SCN-4 human colon adenocarcinomas are serially Passed for 5, 10 and 6 gene- rations. The histologic findings of both original human tumor and those of nude mice were compared. The subpassage tumors resembled those af original ones in terms of differentiation. However, emergence of calcification, extensive necrosis and scanty stroma were distin- guishing features. Although degree of mucin production waa unpredictable during the passages, one colon cancer classified as signet ring cell carcinoma was suceessfully trans- planted and grafted tumor exhibited exactly same histologic feature.

2,157 View
15 Download

Heterotransplantation of Cell Line ( SC-I ) derived from Human Colon Adenocarcinoma in Athymic Nude mice: Han Kwang Yang, Yong Il Kim, Jae Gahb Park, Jin Pok Kim, Woo Ho Kim, Woo Hyun Chang, Mun Ho Lee; J Korean Cancer Assoc. 1985;17(1):55-59.

Abstract PDF: The result of subcutaneous inoculation of SC- I (Seoul National University, Adenocarcin- oma of the Colon) cell line into nude mice is descibed. Twenty-three million and four hundred thousand SC- I cells were injected subcutaneously into the subscapular area of a 28-day-old male nude mouse. After 10 days, tumor was palpable and measured 15.0x7.4x4.0 mm. After 22 days it measured 14.7X12.3x3.7 mm. After 24 days the nude mouse died from unknown cause. Twenty-six million and six hundred thousand SC- I cells were injected subcutaneously into the subscapular area af a 33-day-old male nude mouse. After 3 dys tumor was palpa- ble, but it did not grow any more. On the 26 th day from the first iny. tion, 23. 5x10' SC- I cells were reinjected into the same site of .the same mouse. After 6 days from the second injection, tumor began to grow. After 63 days it measured 22.4x24.0XI2.0 mm and was subpassed to two 33-day-old male nude mice. Histopathologically the tumor produced in the nude mouse showed gland forming tendency with scanty stroma and tumor cells infiltrated into the skeletal muscle of the nude mouse.

2,434 View
15 Download

Determination of Serum CEA Level in Primary Lung Cancer: Jin Hyuk Choi, Jung Hyun Chang, Soon Nam Lee, Eun Mi Nam, Ki Ryung Park, Sa Young Park, Hyo Jin Lee, Sung Min Cho, Young Sun Kim, Ka Eun Woo, Na Young Lee, Na Young Lee, Kwang Ho Kim; J Korean Cancer Assoc. 1996;28(2):281-286.

Abstract PDF: Background
The role of serum carcinoembryonic antigen(CEA) as a tumor marker in primary lung cancer remains unanswered. Several reports suggested that usefulness of serum CEA was limited to specific histologic types or clinical situations. Methods: Serum levels of CEA were determined in 126 patients with primary lung cancer and its correlation with clinico-pathologic characteristics was investigated. Results: Serum CEA was positive (defined as>5ng/ml) in 71 patients(56.3%). The positivity of serum CEA was significantly higher in adenocarcinoma(72.3%) than that in squamous cell carcinoma(46.5%) and small cell carcinoma(44.0%) (p=0.025). There was no significant difference in positivity of CEA according to sex and stages. Conelueion: Serum CEA does not seem to be standard tumor marker of primary lung cancer. However, it could be useful as prognostic factor or monitor of treatment results, especially in adenocarcinoma.

3,464 View
16 Download

First
Prev
Page of 1
Next
Last

Search